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(TU). CHT efficacy were estimated as follows: progression (grade I) – 
increase of area and/or intensity of TU; stabilization (II) – unchanged 
image of BC; partial effect (III) – intermediate (30-70%) decrease in 
intensity and area of TU in BC; prominent efficacy (IV) – only small 
foci of low residual TU in BC; complete resolution (V) – TU in BC on 
the level of background. 
Results: BS detected complete resolution of TU in primary tumor in 10 
(20%) of 50 treated pts, in additional 12 (24%) cases efficacy of CHT 
was prominent, 15 (30%) women had scintigraphic sings of 
stabilization or progression of BC. 
Number of CHT cycles significantly influence character of BS changes. 
After 2 cycles of TAC ± trastuzumab 2 of 10 patients demonstrated 
sings of grade IV, one – of grade III tumor response and other 7- 
stabilization or progression of BC. 
After 3 cycles 7 (44%) of 16 women had good (grade IV-V) efficacy of 
CHT, in other 9 (56%) cases scintigraphic response was moderate or 
poor (grade I-III). 
After 4-6 CHT cycles TU uptake in primary tumor disappeared (V) or 
become markedly reduced (IV) in 13 (54%) of 24 patients. In 6 (25%) 
women BS data reflect non-significant efficacy of CHT. 
Conclusions: BS performed after 4-6 cycles of TAC ± trastuzumab CHT 
indicate that more than a half (56%) of women with advanced BC 
become the candidates for breast irradiation instead of mastectomy.  
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Purpose/Objective: 1) To compare mean heart and left anterior 
descending coronary artery (LAD) doses from left breast radiotherapy 
(RT) delivered using different fractionation schedules and techniques 
(free breathing (FB) versus activated breathing controlled deep 
inspiratory breath-hold (ABC_DIBH).  
2) To define a useable surrogate variable for mean heart and LAD dose 
in order to facilitate plan comparison. 
Materials and Methods: Sixteen patients whose hearts were within 
tangents based on radiotherapy planning CT scans in FB were 
subsequently scanned in ABC_DIBH. Heart, LAD, whole breast/chest 
wall and partial breast clinical target volumes were outlined 
retrospectively. Plans were prepared for each patient and for both 
techniques according to ICRU 62 criteria. DVH data for three different 
fractionation schedules (50Gy/25#, 40Gy/15# and 27Gy/5#) were used 
to determine heart and LAD *NTDmean and NTDmean per fraction as well 
as the volume of heart receiving 25% of the prescribed dose (heart 
V25%) (*NTDmean is a biologically weighted mean of total dose to tissue 
normalised to 2Gy fractions using a standard linear quadratic model). 
In addition the maximum heart depth (MHD) was measured. The 
correlation between heart NTDmean/NTDmean per fraction and both 
heart V25% and MHD was assessed.  
Results: For 27Gy/5#, 40Gy/15# and 50Gy/25# plans respectively, 
mean heart NTDmean for FB plans was 2.7, 3.1 and 3.5Gy (p<0.001) and 
for ABC 0.7, 0.9 and 1.1Gy (p<0.001). Mean LAD NTDmean for FB plans 
was 19.4, 20.1 and 22.6Gy (p<0.001) and for ABC 5.7, 6.4, 7.4Gy 
(p<0.001). Mean heart NTDmean per fraction for FB plans was 0.55, 0.20 
and 0.14Gy (p<0.001) and for ABC 0.14, 0.06 and 0.04Gy (p<0.001). 
Mean LAD NTDmean per fraction for FB plans was 3.88, 1.35 and 0.90Gy 
(p<0.001) and for ABC 1.15, 0.43and 0.30Gy (p<0.001). Linear 
correlation r2 values of0.98 and 0.72 were obtained for the correlation 
between heart NTDmean/heartNTDmean per fraction and heart V25% and 
MHD respectively. 
Conclusions: Heart and LAD NTDmean decrease with the increasingly 
hypofractionated schedules assessed here. In contrast, heart and LAD 
NTDmean per fraction increase with increasingly hypofractionated 
schedules. Heart V25% is a useful and easily derived surrogate for heart 
NTDmean/NTDmean per fraction. 
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Purpose/Objective: To report the 4-year results of accelerated 
partial breast irradiation (APBI) by means of three-dimensional 
conformal radiotherapy (3D-CRT) following breast-conserving surgery 
(BCS) for early-stage breast cancer. 
Materials and Methods: Between 2006 and 2010, in 44 cases of low-
risk, pT1-2 (≤30 mm) pN0 M0 breast cancer, postoperative APBI was 
given by means of 3D-CRT using 3 to 5 non-coplanar fields. The total 
dose of APBI was 36.9 Gy (9 x 4.1 Gy) using a twice-a-day 
fractionation over 5 consecutive days. Four-year survival results, early 
and late toxicities, and cosmetic results were analyzed. 
Results: At a mean follow-up of 47.5 months neither loco-regional nor 
distant failure was observed. No patient died of breast cancer, but 
two of them died of internal disease. The 4-year probability of overall 
survival was 93.3%. Grade 2 or worse acute side-effect was not 
observed. Data on late toxicities and cosmetic results were available 
in 43 cases (97.7%). Grade 1, 2, and 3 fibrosis occurred in 22 (51.2%), 
7 (16.3%), and 1 (2.3%) patients, respectively. Only 4 patients (9.3%) 
developed slight (grade 1) skin hyperpigmentation. No patient 
developed grade 2-4 late skin side effect. Asymptomatic fat necrosis 
was detected in 8 cases (18.6%) on follow-up mammography. 
Excellent, good, fair, and poor cosmetic outcome was reported in 12 
(27.9%), 23 (53.5%), 8 (18.6%), and 0 (0%) patients, respectively. 
Conclusions: 3D-CRT is a feasible technique for the delivery of APBI 
following conservative surgery for the treatment of low-risk, early-
stage invasive breast carcinoma. Four-year results are promising, 
early- and mid-term radiation side effects are rare, and cosmetic 
results are excellent. 
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Purpose/Objective: Different breath movement management 
techniques have been described which effectively spare the heart in 
tangential breast irradiation. The most easy and cheapest way is 
voluntary moderately Deep Inspiration Breath Hold (vmDIBH), but 
reproducibility, and thus actual dose delivery, of this method is 
unclear. The aim of this study is to determine whether the 2D 
measured delivered transit dose is comparable for vmDIBH and free 
breathing (FB) breast irradiations.  
Materials and Methods: Data of 11 patients irradiated during vmDIBH 
and 9 patients irradiated in FB were analyzed. Patients were 
irradiated using a forward IMRT technique to a total dose of 42.7 or 50 
Gy in 16 or 25 fractions,respectively. A Shrinking Action Level (SAL) 
protocol was used for set-up verification using α=10 mm and nmax=3. 
2D transit portal dosimetry was performed for the tangential fields on 
various days, resulting in 386 and 156 measurements for the vmDIBH 
and FB patients, respectively. The delivered transit dose was 
compared to a predicted dose by calculating global gamma values 
with gamma criteria of 3% and 3 mm. The percentage of pixels with an 
absolute gamma value>1 (γ>1) was determined for each measured 
fraction, for both latero-medial and medio-lateral beams. Mean values 
of this parameter were compared between the vmDIBH and FB patient 
groups. Gamma images with more than 5% of the pixels >1 were 
classified as 'failed'. To find an explanation for these failures, these 
gamma images were evaluated visually. If an image showed isolated 
regions of both underdosage and overdosage, gamma and hence dose 
differences were considered to be due to a simple translation 
(residual set-up error or organ motion); if a gamma image showed 
other patterns, dose differences were considered to be due to 
rotation or deformation of the breast.  
Results: The |γ|>1 for all patients was on average 22.0%±10.9% (1 
SD). For the vmDIBH and FB patients, these values were 22.3±11.1% 
and 21.3%±10.5% (1 SD), respectively. No significant difference was 
found (p>0.05). 76% of the gamma images were classified as 'failed', 
77% in vmDIBH patients and 73% in FB patients. In both groups, 24% of 
the 'failures' was attributed to translations. The |γ|>1was 24.4±11.0% 
and 20.2±9.9% (1 SD) for the medio-lateral fields, respectively 
(p>0.05). For the latero-medial fields, these numbers were 22.7±10.8% 
and 24.5± 12.1% (1 SD), respectively (p>0.05) (Figure 1). 
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Conclusions: Dose delivery in breast cancer patients irradiated during 
vmDIBH, as verified in vivo with 2D EPID dosimetry, is as accurate as 
in patients irradiated during FB. 
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Purpose/Objective: The aim of this study was to find out early 
cardiac changes from doxorubicin based chemotherapy and 
radiotherapy in patients with early and locally advanced carcinoma 
breast and to assess cardiac changes in relation to radiation dose 
received by heart. 
Materials and Methods: Investigations like ECG, ECHO and ERV 
(Equilibrium radionuclide ventriculography) were done at baseline, 
after chemotherapy, after radiotherapy and after 6 months of 
followup. Changes in ECG, ECHO and ERV were recorded at different 
time periods during the study. Left ventricular ejection fraction 
(LVEF) was recorded using both ECHO and ERV. In ECHO other 
parameters like Fractional shortening (FS), Mitralvalve E point septal 
separation (MVEPSS) and PEP/LVET ratio (Pre ejectionperiod/Left 
ventricular ejection time) were recorded. Patients were divided into 4 
groups according to the sequence of chemotherapy and radiotherapy. 
Results: The most common ECG change was T wave inversion in the 
pre-cordial leads. One patient had ST depression in V4 & V5 leads and 
2 patients had physiological T wave inversion in Lead III. In Group 1 
mean LVEF (ECHO) at baseline was 66.79 ±3.73. It decreased to 63.45 
± 3.54 after chemotherapy. It further decreased to 61.64 ± 4.26 after 
RT. On follow up there was a further decline to 61.42 ±3.27. In Group 
2 baseline mean LVEF was 66.67 ± 4.33. Post RT it slightlydecreased to 
66 ± 4.975, while post chemotherapyit further declined to 62.7 ± 
2.92.During follow up mean LVEF further decreased to 61.89 ± 2.934. 
In Group 4 baseline mean LVEF was 67.25 ± 4.33, which decreased 
after chemotherapy to 64.75 ± 2.062. During follow up it further 
decreased to 63.25 ± 2.363.  LVEF was also measured by MUGA/ ERV. 
In Group 1 mean LVEF at baseline was 58.14 ±2.997. After 
chemotherapy it decreased to 56.15 ± 3.144. After RT it increased to 
56.21 ± 3.81 and during follow up mean LVEF decreased to 55.21 ± 
2.913. In Group 2 mean LVEF at baseline was 59.11 ± 1.41. Post RT 
decreased to 58.67 ±2.872 and post chemotherapy it decreased to 
54.44 ± 1.81. During follow up it increased to 55.22 ± 1.787. In Group 
4 mean LVEF at baseline was 60 ± 1.63, which decreased to 58.75 ± 
1.89 after chemotherapy. During follow up it further decreased to 
56.25 ± 2.63. 
Conclusions: Our prospective study shows that a significant number of 
patients can develop a transient depression in ventricular function 
after chemotherapy and radiotherapy. ECG changes in our study were 
not specific. T wave inversion was the most common abnormality, 
suggestive of ventricular repolarisation abnormality. Decrease in LVEF 
was seen in our patients both by conventional ECHO and MUGA/ ERV 
scan during different phases of treatment. These changes indicate 
that doxorubicin based chemotherapy and radiotherapy produces 
acute abnormality in left ventricular function. Whether these results 
are predictive of the development of chronic cardiac toxicity can only 
be answered by serially investigating these patients for a longer 
duration. 
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Purpose/Objective: Linear accelerator delivered partial breast 
radiotherapy has a number of advantages over other technologies. 
These include: No new clinical skills, improved efficiency and 
economics, non invasive (vs. brachy), performed with known histology 
(vs. IORT), and ability to deliver accurate and uniform dosimetry. On 
the other hand, uncertainties in target localisation with external 
beam RT has resulted in large PTV expansion margins and increased 
dose to the surrounding normal tissue. This work determines the 
utility of a novel device that allows for accurate localisation and 
patient positioning, facilitating reduced treatment volumes for either 
APBI or breast boost following whole breast RT. 
Materials and Methods: A novel implantable device (BioZorb™ Tissue 
Marker) constructed of standard surgical materials (bio-absorbable 
polymer and Ti clips) has been developed. The polymer is formed into 
a semi-rigid spiral and shaped into a sphere or ellipsoid, with six clips 
strategically placed for visualisation and orientation. A range of sizes 
is available to match the lumpectomy cavity. The implant is placed 
into the cavity at the time of surgery. Several weeks post surgery, 
treatment planning CT (including respiratory gating) is performed. The 
envelope of the implant abutting the margin of the tissue cavity plus 
1cm defines the CTV with an additional 0.5cm expansion for the PTV. 
The treatment is delivered using either 3D conformal or VMAT. Patient 
setup is facilitated with CBCT and a post treatment scan to reveal 
residual error. 
Results: To date 3 patients have been treated using APBI with the 
implant. The average PTV was 84cc compared to 378cc worst case 
using all hyperdense tissue surrounding the cavity, and 788cc for the 
whole breast. The extent of respiratory motion ranged from 0.7 to 
2mm and mean residual error for all measured treatment fractions 
was 1mm (SD 2.3mm). Using a VMAT technique provided further 
enhancement to APBI reducing the non imaging component of 
treatment to 112sec with no floor rotations required and a 36% 
reduction in MU over a non coplanar 3D conformal method. 
 
Conclusions: This novel implantable device provides for greater 
certainty of target definition and assessment of respiratory motion 
when defining the PTV, facilitating the use of IGRT for partial breast 
treatment. Efficient image guided setup further allows for a reduction 
in margin. Post treatment imaging validates the use of a 0.5cm PTV 
expansion. Using this device in the breast parallels the use of other 
fiducially guided treatment sites such as the prostate. When 
positioning the patient, use of the implant serves as a significant 
improvement compared to highly uncertain target surrogates such as 
skin markers or random clips. The device is also able to provide 
certainty of target location in breast boost treatment where there is 
usually limited evidence of the location of the primary site at the 
time of boost.  
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